-+ 0.00%
-+ 0.00%
-+ 0.00%

Gubra Q3 2026 EBIT swings to profit of DKK 317.7 million year-on-year

PUBT·11/06/2026 06:02:19
Listen to the news
Gubra Q3 2026 EBIT swings to profit of DKK 317.7 million year-on-year
  • Gubra swung to Q3 2026 EBIT of DKK 317.7 million from an operating loss a year earlier.
  • Revenue rose year-on-year to DKK 447.7 million; Biotech revenue benefited from partner milestone payments.
  • AbbVie and Boehringer Ingelheim advanced partnered obesity programs into Phase 2 development.
  • Gubra initiated a Phase 1/2a trial of its proprietary GUB-UCN2 program targeting healthier body composition.
  • Full-year 2026 CRO guidance narrowed to 2-6% revenue growth and a 10-13% EBIT margin.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.